Viking Therapeutics Unveils VK2735 Data at ObesityWeek 2025

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is set to present new clinical data on its obesity treatment program, VK2735, at ObesityWeek 2025. This annual meeting, organized by The Obesity Society, will take place from November 4-7, 2025, in Atlanta, Georgia. The company aims to highlight the potential benefits of VK2735, which is a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

One of the key presentations at ObesityWeek will feature findings from the Phase 2 VENTURE clinical trial. This study evaluated the effects of a subcutaneous formulation of VK2735 over a 13-week period in obese subjects. The exploratory analysis will focus on how VK2735 treatment influenced the prevalence of prediabetes and metabolic syndrome among participants.

In addition, Viking will present the design of its ongoing Phase 3 VANQUISH-1 study, which is assessing the efficacy of subcutaneous VK2735 in adults with obesity or those who are overweight and have at least one weight-related comorbidity.

Viking Therapeutics is also scheduled to feature two presentations at the American Heart Association (AHA) Scientific Sessions 2025, occurring from November 7-10, 2025, in New Orleans, Louisiana. These presentations will cover the design of the Phase 3 VANQUISH-2 study, which focuses on patients with Type 2 diabetes who are either obese or overweight. Additionally, a separate poster will analyze the prevalence of cardiometabolic conditions across various body mass index categories.

Details of Upcoming Presentations

The specifics of the presentations at ObesityWeek and the AHA Scientific Sessions are as follows:

**ObesityWeek 2025 Presentations:**

– **Title:** VANQUISH-1 Study Design: Phase 3 Trial of Subcutaneous VK2735 in Adults with Overweight or Obesity
**Presenting Author:** Karen Modesto, M.D., Vice President, Clinical Development, Viking Therapeutics
**Date/Time:** Wednesday, November 5, 2025, 14:30 – 15:30 Eastern Time

– **Title:** Impact of Subcutaneous VK2735 on Weight, Prediabetes, and Cardiometabolic Status: The VENTURE Study
**Presenting Author:** Harold Bays, M.D., MFOMA, FTOS, FACC, FNLA, FASPC, DABOM, Louisville Metabolic and Atherosclerosis Research Center
**Date/Time:** Thursday, November 6, 2025, 14:30 – 15:30 Eastern Time

**AHA Scientific Sessions 2025 Presentations:**

– **Presentation ID:** Sa2063
**Title:** VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Weekly Subcutaneous Administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes
**Presenting Author:** Karen Modesto, M.D., Vice President, Clinical Development, Viking Therapeutics
**Date/Time:** Saturday, November 8, 2025, 10:30 – 11:30 Central Time

– **Presentation ID:** Sa2052
**Title:** Prevalence of Cardiometabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III) Obesity
**Presenting Author:** Saif Rathore, M.D., Ph.D., Sandbar Life Sciences
**Date/Time:** Saturday, November 8, 2025, 14:30 – 15:30 Central Time

Understanding VK2735 and Its Impact

VK2735 has garnered attention for its potential in treating metabolic disorders. The dual activation of GLP-1 and GIP receptors is thought to enhance therapeutic benefits, offering a promising avenue for managing obesity and related conditions.

Research indicates that GLP-1 receptor activation can lead to reduced appetite, weight loss, and improved insulin sensitivity, particularly beneficial for individuals with Type 2 diabetes. Similar dual agonists, such as tirzepatide, have successfully entered the market, showcasing the effectiveness of this therapeutic approach.

Viking Therapeutics continues to evaluate VK2735 in both subcutaneous and oral formulations, with encouraging results from earlier Phase 1 and Phase 2 trials demonstrating a favorable safety profile and potential clinical benefits.

In addition to VK2735, Viking Therapeutics is advancing other therapeutic candidates, including VK2809, targeted for metabolic disorders, and VK0214, aimed at treating rare diseases like X-linked adrenoleukodystrophy.

For further information about Viking Therapeutics and its ongoing research, visit www.vikingtherapeutics.com.